Study of Acute Autoimmune Encephalitis With Positive Antibodies in Eastern France

Study of Acute Autoimmune Encephalitis With Positive Antibodies in Eastern France Between 2006 and 2018

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05605223

Acronym

Encephalitis

Enrollment

Registered

2022-11-04

Start date

2019-06-26

Completion date

2019-12-26

Last updated

2023-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Autoimmune Encephalitis

Keywords

Acute autoimmune encephalitis, encephalitis, autoimmune encephalitis

Brief summary

The number of acute encephalitides diagnosed each year is gradually increasing, reaching approximately 5 to 10/100,000 per year; more than 50% of etiologies currently remain unknown. The majority of them are acute encephalitis of infectious origin, but it is estimated that 20% of encephalitis in northern Europe is related to an autoimmune mechanism with the majority of encephalitis with anti-NMDA Ac discovered recently in 2007. The study of a large American encephalitis cohort showed a death rate of 3% to 7% in cases of autoimmune encephalitis. Furthermore, delay in the initiation of effective treatment (tumor removal or immunotherapy) beyond 4 weeks is associated with a poor prognosis at 1 year. It is therefore necessary to better understand the signs of autoimmune encephalitis in order to recognize the disease quickly and to start a treatment quickly; in order to improve the management and the prognosis of these children.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 17 Years

Healthy volunteers

Inclusion criteria

* Age between 0 and 17 years at diagnosis * Patient diagnosed between 01/01/2006 and 31/12/2018 with autoimmune encephalitis in one of the participating university hospitals (Besançon, Nancy, Strasbourg, Reims and Dijon) * Presence of clinical criteria of clinical and/or radiographic encephalitis * Presence of one or more antibodies in the blood or CSF * Parental authority holders and their child of childbearing age having given their consent for the use of the child's data for this research

Exclusion criteria

* Refusal to participate in the study * Absence of consultation at any of the study centers * Absence of clinical and/or radiographic criteria for encephalitis. * Absence of antibodies found in blood or CSF

Design outcomes

Primary

Measure	Time frame
Retrospective description of autoimmune encephalitis in children	Files analysed retrospectively from January 01, 2006 to December 31, 2018 will be examined

Countries

France

Outcome results